Abstract

Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes have many promising applications, including the regeneration of injured heart muscles, cardiovascular disease modeling, and drug cardiotoxicity screening. Current differentiation protocols yield a heterogeneous cell population that includes pluripotent stem cells and different cardiac subtypes (pacemaking and contractile cells). The ability to purify these cells and obtain well-defined, controlled cell compositions is important for many downstream applications; however, there is currently no established and reliable method to identify hiPSC-derived cardiomyocytes and their subtypes. Here, we demonstrate that second harmonic generation (SHG) signals generated directly from the myosin rod bundles can be a label-free, intrinsic optical marker for identifying hiPSC-derived cardiomyocytes. A direct correlation between SHG signal intensity and cardiac subtype is observed, with pacemaker-like cells typically exhibiting ~70% less signal strength than atrial- and ventricular-like cardiomyocytes. These findings suggest that pacemaker-like cells can be separated from the heterogeneous population by choosing an SHG intensity threshold criteria. This work lays the foundation for developing an SHG-based high-throughput flow sorter for purifying hiPSC-derived cardiomyocytes and their subtypes.

Significance statement

Current differentiation methods for generating human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) yield heterogeneous populations that remain a critical barrier for downstream applications where well-defined populations are required. Markers for identifying undesired populations, such as teratoma-forming or arrhythmia-inducing cells, are not currently available. This study shows a direct correlation between cardiac subtype and the intensity of second harmonic generation (SHG) signals generated from myosin filaments. It also demonstrates SHG signals can be a label-free marker for eliminating undesired cell populations. These results highlight a novel method for using SHG signals to purify hiPSC-CMs.

Myosin filaments are second harmonic generation (SHG) active cellular components that can combine two incident photons and emit a new photon with twice of the energy of an initial photon. The SHG signal is specific to stem cell-derived cardiomyocytes and its signal strength can be used to identify cells by maturity and separate cells by subtype.

INTRODUCTION

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are an ex vivo source of heart cells to potentially treat heart disease, model cardiac cell function and disease, and assess drug cardiotoxicity.1 Purified cell populations with defined compositions are highly desired for these applications. The removal of pluripotent stem cells is critical for human transplantation due to their potential for forming teratomas.2 Moreover, the hiPSC-CMs population itself is a mixture of pacemaker-, atrial-, and ventricular-like subtypes. The elimination of pacemaker-like cells and immature cells that spontaneously generate action potentials (APs) is particularly important to avoid irregular arrhythmic events after cardiac transplantation.3 In drug screening, hiPSC-CMs have an improved prediction of drug response if higher purity cells with more homogenous and desired CM subtype are used.4,, 5

Current hiPSC-CMs differentiation protocols typically yield ~70% CMs with ~15% of the CMs being the pacemaking subtype.6-8 Achieving higher-purity populations is challenging because there is no established purification method, largely due to the lack of a reliable marker that can be used to sort cells by phenotype, maturity, or subtype. Many methods have been explored (eg, lentiviral transduction,9 molecular beacons,10,, 11 size separation,12 metabolic selection,13 mitochondrial dye,14 and surface markers15). These approaches rely on exogenous labels, viruses, or animal derived products that may complicate their use clinically and/or lack the specificity for achieving high-purity cell populations. None of these methods can identify CMs by their subtype.

We previously reported that the second harmonic generation (SHG) signal generated directly from myosin rod bundles can be a highly specific, label-free optical signal for identifying hiPSC-CMs.16 The high specificity is due to myosin filaments only being present in CMs and absent in other types of cells. We further showed that hiPSC-CMs of different maturities could also be discriminated by the SHG intensity due to their myosin development. In this study, we demonstrate that hiPSC-CMs subtypes can be separated based on their SHG intensity due to the different levels of myosin filaments in atrial-, ventricular-, and pacemaker-like hiPSC-CMs.

MATERIALS AND METHODS

Figure 1 illustrates the process we used to identify subtypes of individual hiPSC-CMs and to quantify their total SHG intensity. Detailed descriptions of the methods for cell differentiation, sample preparation, optical measurements, and data analysis are provided in the Supporting Information.

Diagram illustrating the method of identifying the subtype of individual human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and correlating it to their whole-cell second harmonic generation (SHG) intensity. Single cells (40 days in culture) were replated onto gridded glass dishes for 55-67 days for a total of 95-107 days post-differentiation (noted D95 in the manuscript). Cells were loaded with the voltage-sensitive dye FluoVolt. The spontaneous action potentials of individual cells were recorded with a spinning disk fluorescence microscope to measure the time-lapsed fluorescence intensity at ~100 frames per second for ~1 minute. The subtype was determined by the clustering analysis of the action potential (AP) profiles. Cells were then fixed and whole-cell SHG measurements were performed on a multiphoton microscope using a circularly polarized excitation beam. The whole-cell SHG intensity was obtained by performing z-stack imaging and summing the SHG signal intensity from all z-planes. The two-photon fluorescence (2PF) signal from the cell membrane was used as a guide to outline the cell boundary
Figure 1

Diagram illustrating the method of identifying the subtype of individual human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and correlating it to their whole-cell second harmonic generation (SHG) intensity. Single cells (40 days in culture) were replated onto gridded glass dishes for 55-67 days for a total of 95-107 days post-differentiation (noted D95 in the manuscript). Cells were loaded with the voltage-sensitive dye FluoVolt. The spontaneous action potentials of individual cells were recorded with a spinning disk fluorescence microscope to measure the time-lapsed fluorescence intensity at ~100 frames per second for ~1 minute. The subtype was determined by the clustering analysis of the action potential (AP) profiles. Cells were then fixed and whole-cell SHG measurements were performed on a multiphoton microscope using a circularly polarized excitation beam. The whole-cell SHG intensity was obtained by performing z-stack imaging and summing the SHG signal intensity from all z-planes. The two-photon fluorescence (2PF) signal from the cell membrane was used as a guide to outline the cell boundary

RESULTS AND DISCUSSION

The subtype of each hiPSC-CMs was first determined by its AP profile through the clustering analysis, an established alternative method to patch clamp for subtype classification.8, 17-19 The AP of a ventricular-like cell shows a more prominent plateau phase than that of an atrial-like and pacemaker-like cell (Figure 2A1-A3). Moreover, ventricular-like cells have an average AP duration (APD50, AP duration at 50% repolarization) near 324 ± 20 ms, which is longer than that of atrial-like cells (166 ± 4 ms) and pacemaker-like cells (171 ± 8 ms). The average membrane voltage change of pacemaker-like cells is ~15% (ΔF/F0, the maximum change in fluorescence), whereas contractile CMs have a higher amplitude of ~21%. See graphs in Figure S1 in Supporting Information. Among all 200 cells that were sampled, pacemaker-like hiPSC-CMs represent the smallest population at 10%, whereas the ventricular-like and atrial-like cells account for 44% and 46%, respectively. This subtype distribution is comparable to previously published reports.8, 20-22

A, Representative action potential profiles used to classify the cardiomyocyte subtype of each cell (V, ventricular-like; A, atrial-like; P, pacemaking-like human-induced pluripotent stem cell-derived cardiomyocytes). B, Representative whole-cell second harmonic generation (SHG) images show that the contractile cells exhibit more organized sarcomeric striation patterns, whereas the pacemaker-like cells typically have a lower SHG signal intensity from less organized sarcomeric structures. C, Average whole-cell SHG intensities for each cardiac subtype. The SHG signal strength of pacemaker-like cells is ~70% less than that of the contractile cells. The average whole-cell SHG intensity ± SE for ventricular-like, atrial-like, and pacemaking-like cells are 40 ± 9, 34 ± 5, and 11 ± 2 million A.U., respectively. A Kruskal-Wallis test was used to assess the significance of the difference in SHG intensities between subtypes. P-values were greater than .05, indicating the differences were nonsignificant (ns). The distribution of SHG intensity for all cells of each subtype is shown in the histograms in Figure 3
Figure 2

A, Representative action potential profiles used to classify the cardiomyocyte subtype of each cell (V, ventricular-like; A, atrial-like; P, pacemaking-like human-induced pluripotent stem cell-derived cardiomyocytes). B, Representative whole-cell second harmonic generation (SHG) images show that the contractile cells exhibit more organized sarcomeric striation patterns, whereas the pacemaker-like cells typically have a lower SHG signal intensity from less organized sarcomeric structures. C, Average whole-cell SHG intensities for each cardiac subtype. The SHG signal strength of pacemaker-like cells is ~70% less than that of the contractile cells. The average whole-cell SHG intensity ± SE for ventricular-like, atrial-like, and pacemaking-like cells are 40 ± 9, 34 ± 5, and 11 ± 2 million A.U., respectively. A Kruskal-Wallis test was used to assess the significance of the difference in SHG intensities between subtypes. P-values were greater than .05, indicating the differences were nonsignificant (ns). The distribution of SHG intensity for all cells of each subtype is shown in the histograms in Figure 3

The contractile cells (ie, ventricular-like and atrial-like) on average exhibit a higher SHG intensity than pacemaker-like cells (Figure 2B,C; V: 40-, A: 34-, P: 11-million counts). For contractile cells, the SHG signals originate from relatively periodic, organized sarcomere patterns in the cells, whereas the pacemaker-like cells have lower intensity counts and the signal is distributed across the cell from a less-organized myosin network (Figure 2B1-B3). On average, contractile cells generate >3.5 times more signal than pacemaker-like cells.

A Kruskal-Wallis test performed on the results in Figure 2C indicates that the SHG intensities are not statistically different between the three groups. However, more detailed information of the cell-to-cell variability of the SHG intensity for each subtype can be obtained by plotting histograms from the three cell groups (Figure 3). All pacemaker-like cells have signal intensity less than 30 × 106 counts. In contrast, the contractile cells have a wider distribution: the atrial-like and ventricular-like populations have cells that exhibit SHG intensities up to ~200 × 106 and ~500 × 106 counts, respectively. Many of these contractile cells, however, also exhibit low SHG signal intensities. These cells tend to be smaller and have a partially developed, disordered myofilament network, which is in stark contrast to the ordered, well-developed myosin network of adult contractile CMs (Figure S2) that emit strong SHG signals.

Histogram plots of whole-cell second harmonic generation (SHG) intensity for each cardiomyocyte subtype. The dashed line indicates an SHG signal threshold of 30 × 106 counts that can be used to separate pacemaker-like cells from the other cells
Figure 3

Histogram plots of whole-cell second harmonic generation (SHG) intensity for each cardiomyocyte subtype. The dashed line indicates an SHG signal threshold of 30 × 106 counts that can be used to separate pacemaker-like cells from the other cells

These results suggest that by selecting an SHG intensity threshold criteria (i.e., 30 × 106 counts in this case), it is possible to purge potential arrhythmia-inducing pacemaker-like cells from a population of hiPSC-CMs and retrieve a pure population of contractile cells. The tradeoff, however, is that a fraction of contractile cells would also be lost. We estimated that about 66% of the contractile cells would be discarded along with all pacemaker-like cells. About 30% of the total cell population, comprised of only contractile cells, can be recovered with this technique (Figure 4).

Histogram of the whole-cell second harmonic generation (SHG) intensity with a 30 × 106 intensity increment. The dashed line indicates the 30 × 106 intensity threshold that will filter ~70% of cells, including all pacemaker-like cells. The remaining 30% of gated cells (inset plot) are all atrial- and ventricular-like cells
Figure 4

Histogram of the whole-cell second harmonic generation (SHG) intensity with a 30 × 106 intensity increment. The dashed line indicates the 30 × 106 intensity threshold that will filter ~70% of cells, including all pacemaker-like cells. The remaining 30% of gated cells (inset plot) are all atrial- and ventricular-like cells

It may be possible to improve the recovery rate of contractile cells by optimizing parameters such as differentiation time, replating time, substrate stiffness, or electrical stimulation of cells to mature myosin development and increase SHG signal strength.23,, 24 For example, we performed the same experiment on D53 cells post-differentiation that have a shorter replating time (ie, 10 days after replating) and compared the results to the D95 cells post-differentiation (Figure S3). We observed similar overall trends in the SHG intensities of the three cardiac subtypes indicating good data reproducibility. Also, if the same SHG intensity threshold is used, the number of contractile cells that would fall within the pacemaker-like cell population slightly decreases. As such, for D53 cells, ~60% of the contractile cells would be discarded. hiPSC-derived contractile CMs are known to exhibit a decrease in frequency of automaticity over time in culture, which can adversely affect myofilament development without an external electrical stimulus.22,, 25 Therefore, single-plated contractile CMs, as in D95 CMs, may have loss of myofilaments with long-term culture. The higher whole-cell SHG signal counts in D53 hiPSC-derived contractile CMs is presumably due to these cells retaining their contractile structure before further reduction of automaticity frequency. As maturation strategies for hiPSC-derived contractile CMs improve,22 the separation between pacemaker and contractile phenotype may be more distinct, since it is known that pacemaking cells have underdeveloped and poorly organized myofilaments compared to contractile cells in vivo, in humans and other animals.26 Hence, the SHG signal intensities, which depend on myosin filament content, will be more distinct for these two cell groups, enabling improved contractile cell yield and reduced numbers of discarded false-negative contractile CMs.

CONCLUSION

We demonstrate that, in addition to being able to identify hiPSC-CMs,16 SHG signals can be also used as a label-free optical marker to remove pacemaker-like cells from a heterogeneous population. By selecting a proper SHG intensity threshold criteria, as is commonly done in flow cytometry, cells that might form teratomas (ie, undifferentiated hiPSCs with no SHG signal) or induce arrhythmias (ie, pacemaker-like cells with a low SHG intensity) can be identified in a label-free, noninvasive manner. Although we used a confocal microscope in this study to accurately quantify whole-cell SHG signal intensities, we are actively working on integrating SHG into a microfluidic sorting system for analyzing individual hiPSC-CMs prepared as suspension cells using collagenase.16 SHG has the potential to be a novel nonlinear optical modality in flow cytometry27 for high-throughput purification of hiPSC-CMs to obtain sorted cell populations with well-defined cell compositions that can be used in disease modeling, drug screening, and stem cell based therapies.

ACKNOWLEDGMENTS

This work was supported by grants from National Science Foundation (1827611) (to J.W.C.) and California Institute for Regenerative Medicine (DISC2-10120) (to D.K.L.). C.-W. Chang acknowledges the support from the T32 Training Program in Basic and Translational Cardiovascular Science established by National Heart, Lung and Blood Institute (T32 HL086350). We thank Nipavan Chiamvimonvat's laboratory for providing the adult mouse cardiomyocytes.

CONFLICT OF INTEREST

D.K.L. serves as a consultant for Novoheart Ltd. The other authors indicate no potential conflict of interest.

AUTHOR CONTRIBUTIONS

C.-W.C.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; H.K.J.K.: conception and design, manuscript writing, provision of study materials, data interpretation; S.Y.: conception and design, data analysis and interpretation; D.K.L., J.W.C.: conception and design, data analysis and interpretation, manuscript writing, financial support, final approval of manuscript.

DATA AVAILABILITY STATEMENT

The data supporting the findings are available from the corresponding author upon reasonable request.

REFERENCES

1

Oikonomopoulos
 
A
,
Kitani
 
T
,
Wu
 
JC
.
Pluripotent stem cell-derived cardiomyocytes as a platform for cell therapy applications: progress and hurdles for clinical translation
.
Mol Ther
.
2018
;
26
:
1624
-
1634
.

2

Nelakanti
 
RV
,
Kooreman
 
NG
,
Wu
 
JC
.
Teratoma formation: a tool for monitoring pluripotency in stem cell research
.
Curr Protoc Stem Cell Biol
.
2015
;
32
:
4A.8.1
-
4A.8.17
.

3

Almeida
 
SO
,
Skelton
 
RJ
,
Adigopula
 
S
,
Ardehali
 
R
.
Arrhythmia in stem cell transplantation
.
Card Electrophysiol Clin
.
2015
;
7
:
357
-
370
.

4

Kawatou
 
M
,
Masumoto
 
H
,
Fukushima
 
H
, et al.
Modelling torsade de pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue
.
Nat Commun
.
2017
;
8
:
1078
.

5

Moretti
 
A
,
Bellin
 
M
,
Welling
 
A
, et al.
Patient-specific induced pluripotent stem-cell models for long-QT syndrome
.
N Engl J Med
.
2010
;
363
:
1397
-
1409
.

6

Burridge
 
PW
,
Keller
 
G
,
Gold
 
JD
,
Wu
 
JC
.
Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming
.
Cell Stem Cell
.
2012
;
10
:
16
-
28
.

7

Burridge
 
PW
,
Matsa
 
E
,
Shukla
 
P
, et al.
Chemically defined generation of human cardiomyocytes
.
Nat Methods
.
2014
;
11
:
855
-
860
.

8

Yechikov
 
S
,
Copaciu
 
R
,
Gluck
 
JM
, et al.
Same-single-cell analysis of pacemaker-specific markers in human induced pluripotent stem cell-derived cardiomyocyte subtypes classified by electrophysiology
.
Stem Cells
.
2016
;
34
:
2670
-
2680
.

9

Woods
 
NB
,
Muessig
 
A
,
Schmidt
 
M
, et al.
Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis
.
Blood
.
2003
;
101
:
1284
-
1289
.

10

Wile
 
BM
,
Ban
 
K
,
Yoon
 
YS
,
Bao
 
G
.
Molecular beacon-enabled purification of living cells by targeting cell type-specific mRNAs
.
Nat Protoc
.
2014
;
9
:
2411
-
2424
.

11

Heyduk
 
E
,
Knoll
 
E
,
Heyduk
 
T
.
Molecular beacons for detecting DNA binding proteins: mechanism of action
.
Anal Biochem
.
2003
;
316
:
1
-
10
.

12

Xu
 
C
,
Police
 
S
,
Rao
 
N
,
Carpenter
 
MK
.
Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells
.
Circ Res
.
2002
;
91
:
501
-
508
.

13

Tohyama
 
S
,
Hattori
 
F
,
Sano
 
M
, et al.
Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes
.
Cell Stem Cell
.
2013
;
12
:
127
-
137
.

14

Hattori
 
F
,
Chen
 
H
,
Yamashita
 
H
, et al.
Nongenetic method for purifying stem cell-derived cardiomyocytes
.
Nat Methods
.
2010
;
7
:
61
-
66
.

15

Dubois
 
NC
,
Craft
 
AM
,
Sharma
 
P
, et al.
SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells
.
Nat Biotechnol
.
2011
;
29
:
1011
-
1018
.

16

Awasthi
 
S
,
Matthews
 
DL
,
Li
 
RA
,
Chiamvimonvat
 
N
,
Lieu
 
DK
,
Chan
 
JW
.
Label-free identification and characterization of human pluripotent stem cell-derived cardiomyocytes using second harmonic generation (SHG) microscopy
.
J Biophotonics
.
2012
;
5
:
57
-
66
.

17

Takaki
 
T
,
Inagaki
 
A
,
Chonabayashi
 
K
, et al.
Optical recording of action potentials in human induced pluripotent stem cell-derived cardiac single cells and monolayers generated from long QT syndrome type 1 patients
.
Stem Cells Int
.
2019
;
2019
:
7532657
.

18

Bedut
 
S
,
Seminatore-Nole
 
C
,
Lamamy
 
V
, et al.
High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes
.
Am J Physiol Heart Circ Physiol
.
2016
;
311
:
H44
-
H53
.

19

Biendarra-Tiegs
 
SM
,
Secreto
 
FJ
,
Nelson
 
TJ.
 Addressing variability and heterogeneity of induced pluripotent stem cell-derived cardiomyocytes. In:
Advances in Experimental Medicine and Biology
.
New York, NY
:
Springer
;
2019
.

20

Ma
 
J
,
Guo
 
L
,
Fiene
 
SJ
, et al.
High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents
.
Am J Physiol Heart Circ Physiol
.
2011
;
301
:
H2006
-
H2017
.

21

He
 
JQ
,
Ma
 
Y
,
Lee
 
Y
,
Thomson
 
JA
,
Kamp
 
TJ
.
Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization
.
Circ Res
.
2003
;
93
:
32
-
39
.

22

Lieu
 
DK
,
Fu
 
JD
,
Chiamvimonvat
 
N
, et al.
Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes
.
Circ Arrhythm Electrophysiol
.
2013
;
6
:
191
-
201
.

23

Ribeiro
 
AJ
,
Ang
 
YS
,
Fu
 
JD
, et al.
Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness
.
Proc Natl Acad Sci USA
.
2015
;
112
:
12705
-
12710
.

24

Engler
 
AJ
,
Carag-Krieger
 
C
,
Johnson
 
CP
, et al.
Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating
.
J Cell Sci
.
2008
;
121
:
3794
-
3802
.

25

Sartiani
 
L
,
Bettiol
 
E
,
Stillitano
 
F
,
Mugelli
 
A
,
Cerbai
 
E
,
Jaconi
 
ME
.
Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach
.
Stem Cells
.
2007
;
25
:
1136
-
1144
.

26

Boyett
 
MR
,
Honjo
 
H
,
Kodama
 
I
.
The sinoatrial node, a heterogeneous pacemaker structure
.
Cardiovasc Res
.
2000
;
47
:
658
-
687
.

27

Collier
 
BB
,
Awasthi
 
S
,
Lieu
 
DK
, et al.
Non-linear optical flow cytometry using a scanned, Bessel beam light-sheet
.
Sci Rep
.
2015
;
5
:10751.

Author notes

Funding information California Institute for Regenerative Medicine, Grant/Award Number: DISC2-10120; National Science Foundation, Grant/Award Number: 1827611; National Institutes of Health, Grant/Award Number: T32 HL086350

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Supplementary data